Evolving Regulatory Strategy with Cell Therapy Innovation
- Clarifying CAR-T FDA regulations within existing biologics frameworks to understand current expectations for CMC, preclinical, and clinical development
- Examining FDA regulatory considerations for emerging in vivo and innovative CAR products to highlight where requirements diverge from ex vivo cell therapies
- Adapting development and regulatory strategies to align with evolving FDA guidance, to advance novel cell therapy programs